Evidence map›Paper›PMID 37088833›Full record

ArticleCEN case reports2024

IgA nephropathy in a boy with frequently relapsing nephrotic syndrome.

Yuta Ichikawa, Tomoko Horinouchi, Yu Tanaka, Chika Ueda, Hideaki Kitakado, Atsushi Kondo, Nana Sakakibara, Norishige Yoshikawa, Kandai Nozu

Open access · greenAbstract readCase Reports
In one paragraph

Article in CEN case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 93% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Yuta IchikawaDepartment of Pediatrics, Kobe University Graduate School of Medicine, Kusunokicho 7-5-1, Chuo-Ku, Kobe, Hyogo, 650-0017, Japan.
Tomoko HorinouchiDepartment of Pediatrics, Kobe University Graduate School of Medicine, Kusunokicho 7-5-1, Chuo-Ku, Kobe, Hyogo, 650-0017, Japan. tohori@med.kobe-u.ac.jp.ORCID 0000-0003-1655-6030
Yu TanakaDepartment of Pediatrics, Kobe University Graduate School of Medicine, Kusunokicho 7-5-1, Chuo-Ku, Kobe, Hyogo, 650-0017, Japan.
Chika UedaDepartment of Pediatrics, Kobe University Graduate School of Medicine, Kusunokicho 7-5-1, Chuo-Ku, Kobe, Hyogo, 650-0017, Japan.
Hideaki KitakadoDepartment of Pediatrics, Kobe University Graduate School of Medicine, Kusunokicho 7-5-1, Chuo-Ku, Kobe, Hyogo, 650-0017, Japan.
Atsushi KondoDepartment of Pediatrics, Kobe University Graduate School of Medicine, Kusunokicho 7-5-1, Chuo-Ku, Kobe, Hyogo, 650-0017, Japan.
Nana SakakibaraDepartment of Pediatrics, Kobe University Graduate School of Medicine, Kusunokicho 7-5-1, Chuo-Ku, Kobe, Hyogo, 650-0017, Japan.
Norishige YoshikawaClinical Research Center, Takatsuki General Hospital, 1-3-13 Kosobe-Cho, Takatsuki, Osaka, Japan.
Kandai NozuDepartment of Pediatrics, Kobe University Graduate School of Medicine, Kusunokicho 7-5-1, Chuo-Ku, Kobe, Hyogo, 650-0017, Japan.
Kobe University · JPTakatsuki General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A Japanese boy developed nephrotic syndrome (NS) and had microscopic hematuria at 8 years old. Renal biopsy was performed. Light microscopy study revealed mesangial proliferation and all immunofluorescent stains (including IgA) were negative, so he was diagnosed with non-IgA diffuse mesangial proliferation (DMP). Complete remission was achieved at 13 days after the initiation of oral prednisolone, and hematuria also disappeared 3 days later, but the patient developed frequently relapsing nephrotic syndrome. Cyclosporine A (CyA) was introduced at 10 years old, and there were no relapses between then and when it was discontinued at 12 years old. A second renal biopsy revealed minimal change without CyA nephrotoxicity. However, there was repeated relapse of NS after discontinuation, so CyA was reintroduced 8 months later, and NS remained in remission thereafter. Microscopic hematuria appeared at 13 years old, however, with gross hematuria appearing at the time of infection. A third renal biopsy revealed mesangial proliferation with IgA-dominant deposition, so the patient was diagnosed with IgA nephropathy. Currently (14 years old), CyA treatment has been discontinued and the patient is undergoing lisinopril therapy for IgA nephropathy, but there are still relapses of NS. To the best of our knowledge, there have been no previous reports of a patient with non-IgA DMP at the onset of NS who had later development of IgA nephropathy. The patient showed non-IgA DMP at the onset, suggesting that NS with non-IgA DMP and IgA nephropathy has some common pathophysiology. Treatment for NS, such as PSL and/or CyA treatment, may suppress the clinical manifestation of late IgA nephropathy.

Indexed as

Glomerulonephritis, IGANephrotic SyndromeAdolescentChildChronic DiseaseCyclosporineHematuriaHumansImmunoglobulin AMalePrednisoloneRecurrenceCyclosporineImmunoglobulin APrednisoloneCyclosporine A (CyA)Frequently relapsing nephrotic syndrome (FRNS)IgA nephropathyNephrotic syndrome (NS)Non-IgA diffuse mesangial proliferation (DMP)

Identifiers

PMID37088833
PMCPMC10834886
OpenAlexW4366821641

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.